A pharmacological approach to panic disorder during pregnancy

References

• Vicente B, Kohn R, Rioseco P, et al. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile Psychiatric Prevalence Study. Am J Psychiatry 2006;163:1362–70
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment Area Study. Acta Psychiatr Scand 1993;88:35–47
   PubMed Web of Science ®Google Scholar
• Burke KC, Burke JD, Regier DA, Rae DS. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990;47:511–18
   PubMed Web of Science ®Google Scholar
• Andersson L, Sundström-Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003;189:148–54
   PubMed Web of Science ®Google Scholar
• Andersson L, Sundström-Poromaa I, Wulff M, et al. Depression and anxiety disorder during pregnancy and six months postpartum: a follow-up study. Acta Obstet Gynecol Scand 2006;85:937–44
   PubMed Web of Science ®Google Scholar
• Adewuya AO, Ola BA, Aloba OO, Mapayi BM. Anxiety disorders among Nigerian women in late pregnancy: a controlled study. Arch Womens Ment Health 2006;9:325–8
   PubMed Web of Science ®Google Scholar
• Felice E, Saliba J, Grech V, et al. Antenatal psychiatric morbidity in Maltase women. Gen Hosp Psychiatry 2007;29:501–5
   PubMed Web of Science ®Google Scholar
• Borri C, Mauri M, Oppo A, et al. Axis I psychopathology and functional impairment at the third month of pregnancy: results from the Perinatal Depression-Research and Screening Unit (PND-ReScU) Study. J Clin Psychiatry 2008;69:1617–24
   PubMed Web of Science ®Google Scholar
• Farias DR, Pinto TdeJ, Teofilo MM, et al. Prevalence of psychiatric disorders in the first trimester of pregnancy and factors associated with current suicide risk. Psychiatry Res 2013;210:962–8
   PubMed Web of Science ®Google Scholar
• Guler O, Kır FG, Emul HM, et al. The prevalence of panic disorder in pregnant women during the third trimester of pregnancy. Compr Psychiatry 2008;49:154–8
   PubMed Web of Science ®Google Scholar
• Uguz F, Gezginc K, Kayhan F, et al. Is pregnancy associated with mood and anxiety disorders? A cross-sectional study. Gen Hosp Psychiatry 2010;32:213–15
   PubMed Web of Science ®Google Scholar
• Bandelow B, Sojka F, Broocks A, et al. Panic disorder during pregnancy and postpartum period. Eur Psychiatry 2006;21:495–500
   PubMed Web of Science ®Google Scholar
• Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Impact of pregnancy on panic disorder: a case series. J Clin Psychiatry 1994;55:284–8
   PubMed Web of Science ®Google Scholar
• Cohen LS, Sichel DA, Faraone SV, et al. Course of panic disorder during pregnancy and the puerperium: a preliminary study. Biol Psychiatry 1996;39:950–4
   PubMed Web of Science ®Google Scholar
• Sjöström K, Valentin L, Thelin T, Maršal K. Maternal anxiety in late pregnancy and fetal hemodynamics. Eur J Obstet Gynecol Reprod Biol 1997;74:149–55
   PubMed Web of Science ®Google Scholar
• Sanchez SE, Puente GC, Atentico G, et al. Risk of spontaneous preterm birth in relation to maternal depressive, anxiety and stress symptoms. J Reprod Med 2013;58:25–33
   PubMed Web of Science ®Google Scholar
• Loomans EM, van der Stelt O, van Eijsden M, et al. Antenatal maternal anxiety is associated with problem behaviour at age five. Early Hum Dev 2011;87:656–70
   Web of Science ®Google Scholar
• Buss C, Davis EP, Hobel CJ, Sandman CA. Maternal pregnancy-specific anxiety is associated with child executive function at 6–9 years age. Stress 2011;14:665–76
   PubMed Web of Science ®Google Scholar
• Leis JA, Heron J, Stuart EA, Mendelson T. Associations between maternal mental health and child emotional and behavioral problems: does prenatal mental health matter? J Abnorm Child Psychol 2014;42:161–71
   PubMed Web of Science ®Google Scholar
• Talge NM, Neal C, Glover V, the Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry 2007;48:245–61
   PubMed Web of Science ®Google Scholar
• Ding XX, Wu YL, Xu SJ, et al. Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies. J Affect disord 2014;159:103–10
   PubMed Web of Science ®Google Scholar
• Van Batenburg-Eddes T, Brion MJ, Henrichs J, et al. Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study. J Child Psychol Psychiatry 2013;54:591–600
   PubMed Web of Science ®Google Scholar
• Glover V. Maternal depression, anxiety and stress during pregnancy and child outcome: what needs to be done. Best Pract Res Clin Obstet Gynecol 2014;28:25–35
   PubMed Web of Science ®Google Scholar
• Chen YH, Lin HC, Lee HC. Pregnancy outcomes among women with panic disorder – do panic attacks during pregnancy matter? J Affect Disord 2010;120:258–62
   PubMed Web of Science ®Google Scholar
• Bánhidy F, Ács N, Puhó E, Czeizel AE. Association between maternal panic disorders and pregnancy complications and delivery outcomes. Eur J Obstet Gynecol Reprod Biol 2006;124:47–52
   PubMed Web of Science ®Google Scholar
• Ács N, Bánhidy F, Horváth-Puhó E, et al. Maternal panic disorder and congenital abnormalities: a population-based case–control study. Birth Defetcts Res A Clin Mol Teratol 2006;76:253–61
   PubMed Web of Science ®Google Scholar
• Uguz F, Sahingoz M, Sonmez EO, et al. The effects of maternal major depression, generalized anxiety disorder, and panic disorder on birth weight and gestational age: a comparative study. J Psychosom Res 2013;75:87–9
   PubMed Web of Science ®Google Scholar
• Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011;24:34–40
   PubMed Web of Science ®Google Scholar
• Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010;30:249–60
   PubMed Web of Science ®Google Scholar
• Malm H, Artama M, Gissler M, Ritvanem A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111–20
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403–13
   PubMed Web of Science ®Google Scholar
• Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust NZ J Psychiatry 2010;44:978–96
   PubMed Web of Science ®Google Scholar
• Myles N, Newall H, Ward H, Matthew L. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust NZ J Psychiatry 2013;47:1002–12
   PubMed Web of Science ®Google Scholar
• Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74:e293–308
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, et al. First trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. NEJM 2007;356:2675–83
   PubMed Web of Science ®Google Scholar
• Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127:94–114
   PubMed Web of Science ®Google Scholar
• Lorenzo L, Byers B, Einarson A. Antidepressant use in pregnancy. Expert Opin Drug Saf 2011;10:883–9
   PubMed Web of Science ®Google Scholar
• Riggin L, Frankel Z, Moretti M, et al. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can 2013;35:362–9
   PubMedGoogle Scholar
• Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918–26
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. BJCP 2008;66:695–705
   Web of Science ®Google Scholar
• Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnancy and postpartum women. Annu Rev Clin Psychol 2014;10:369–92
   PubMed Web of Science ®Google Scholar
• Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol 2010;686:349–64
   PubMed Web of Science ®Google Scholar
• Sadowski SL. Congenital cardiac disease in the newborn infant: past, present, and future. Crit Care Nurs Clin North Am 2009;21:37–48
   PubMedGoogle Scholar
• Klieger-Grossmann C, Weitzner B, Panchaud A, et al. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol 2012;52:766–70
   PubMed Web of Science ®Google Scholar
• Bellantuono C, Bozzi F, Orsolini L, Catena-Dell'Osso M. The safety of escitalopram durng pregnancy and breasfeeding: a comprehensive review. Hum Psychopharmacol 2012;27:534–9
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Norwitz ER, Smith MV, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 2012;23:677–85
   PubMed Web of Science ®Google Scholar
• Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949–54
   PubMedGoogle Scholar
• Huang H, Coleman S, Bridge JA, et al. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry 2014;36:13–18
   PubMed Web of Science ®Google Scholar
• Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication. JAMA Psychiatry 2013;70:436–43
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One 2014;9:e92778
   PubMed Web of Science ®Google Scholar
• Lewis AJ, Galbally M, Opie G, Buist A. Neonatal growth outcomes at birth an done month postpartum following in utero exposure to antidepressant medication. Aust NZ J Psychiatry 2010;44:482–7
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898–906
   PubMed Web of Science ®Google Scholar
• Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206–13
   PubMed Web of Science ®Google Scholar
• Roca A, Garcia-Esteve LI, Imaz ML, et al. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J Affect Disord 2011;135:208–15
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008;192:338–43
   PubMed Web of Science ®Google Scholar
• Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557–66
   PubMed Web of Science ®Google Scholar
• Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182:1031–7
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru J Pharm Sci 2012;20:75
   Web of Science ®Google Scholar
• Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246–52
   PubMed Web of Science ®Google Scholar
• Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012;12:344
   Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertention of the newborn. N Eng J Med 2006;354:579–87
   PubMed Web of Science ®Google Scholar
• Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonray hypertention of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012;169:134–40
   PubMed Web of Science ®Google Scholar
• Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonray hypertention of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19–24
   PubMed Web of Science ®Google Scholar
• Källén B, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertention of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801–6
   PubMed Web of Science ®Google Scholar
• Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932
   PubMed Web of Science ®Google Scholar
• Nulman I, Koren G, Rovet J, et al. Nurodevelopment of children following prenatal exposure to venlafaxine, selectiveserotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012;169:1165–74
   PubMed Web of Science ®Google Scholar
• Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1–9
   PubMed Web of Science ®Google Scholar
• Smith MV, Sung A, Shah B, et al. Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum Dev 2013;89:81–6
   PubMed Web of Science ®Google Scholar
• Idring S, Rai D, Dalman C, et al. Autism spectrum disorders in the Stockholm Youth Cohort: design, prevalence and validity. PLoS One 2012;7:e41280
   PubMed Web of Science ®Google Scholar
• Rai D, Lee BK, Dalman C, et al. Prenatal depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case–control study. BMJ 2013;346:f2059
   PubMed Web of Science ®Google Scholar
• Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104–12
   PubMed Web of Science ®Google Scholar
• Sørensen MJ, Grønborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013;5:449–59
   PubMedGoogle Scholar
• Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat 2013;9:1257–66
   PubMed Web of Science ®Google Scholar
• Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. Literature review and implications for clinical applications. JAMA 2005;293:2372–83
   PubMed Web of Science ®Google Scholar
• Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005;25:595–604
   PubMedGoogle Scholar
• Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Cin Psychiatry 2013;74:e309–20
   PubMed Web of Science ®Google Scholar
• Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf 2014;13:207–25
   PubMed Web of Science ®Google Scholar
• Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280–4
   PubMed Web of Science ®Google Scholar
• Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013;35:3–8
   PubMed Web of Science ®Google Scholar
• Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case–control studies. BMJ 1998;317:839–43
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulltein. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008;111:1001–120
   PubMedGoogle Scholar
• Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39–49
   PubMed Web of Science ®Google Scholar
• Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203–10
   PubMed Web of Science ®Google Scholar
• Marchesi C. Pharmacological management of panic disorder. Neuropsychiatr Dis Treat 2008;4:93–106
   PubMedGoogle Scholar
• Bandelow B, Rüther E. Treatment-resistant panic disorder. CNS Spectr 2004;9:725–39
   PubMed Web of Science ®Google Scholar
• Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol 2012;15:403–15
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A, Calati R, et al. Novel antidepressants and panic disorder: evidence beyond current guidelines. Neuropsychobiology 2011;63:1–7
   PubMed Web of Science ®Google Scholar
• Uguz F, Sahingoz M, Gungor B, Askin R. Low-dose imipramine for treatment of panic disorder during pregnancy: a retrospective chart review. J Clin Psychopharmacol 2014;34:513–15
   PubMed Web of Science ®Google Scholar
• Caillard V, Roullion F, Viel JF, Markabi S. Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. Acta Psychiatr Scand 1999;99:51–8
   PubMed Web of Science ®Google Scholar
• Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defects. Reprod Toxicol 2006;21:221–2
   PubMed Web of Science ®Google Scholar
• Källén B, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defects. Reprod Toxicol 2003;17:255–61
   PubMed Web of Science ®Google Scholar
• Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol 2013;28:33–45
   PubMed Web of Science ®Google Scholar
• Uguz F. Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. J Matern Fetal Neonatal Med 2013;26:1066–8
   PubMed Web of Science ®Google Scholar
• Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013;82:355–62
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to selective serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68–76
   PubMed Web of Science ®Google Scholar
• Anderson G. Pregnancy-induced changes in pharmacokinetics. A mechanistic-based approach. Clin Phramcokinet 2005;44:989–1008
   PubMed Web of Science ®Google Scholar
• Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of parmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol 2014;34:244–55
   PubMed Web of Science ®Google Scholar
• Freeman MP, Nolan PE, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008;28:646–53
   PubMed Web of Science ®Google Scholar
• Ter Horst PG, Larmené-Beld KH, Bosman J, et al. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J Clin Pharm Ther 2014;39:541--4
   PubMed Web of Science ®Google Scholar
• Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;69:652–8
   PubMed Web of Science ®Google Scholar
• Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998;155:1570–7
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36–42
   PubMed Web of Science ®Google Scholar
• Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549–53
   PubMed Web of Science ®Google Scholar
• Simon NM, Worthington JJ, Thompson EH, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy. J Clin Psychiatry 2009;70:1563–70
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR. Sertraline in panic disorder: initial treatment versus switch strategy. J Clin Psychopharmacol 2003;23:646–51
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR. Switching from imipramine to sertraline in panic disorder. J Psychiatr Pract 2004;10:88–94
   PubMedGoogle Scholar
• Källén B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 2012;32:608–14
   PubMed Web of Science ®Google Scholar